TY - JOUR T1 - A Randomized Control Study Comparing Efficacy and Safety of Daily Oral Corticosteroids and Minipulse Therapy in Treatment of Rapidly Progressive Non Segmental Vitiligo AU - Sreeparvathi, P.A. AU - Pravin, A.J.S. AU - Jaffer, Azeem AU - Simon, J. JO - Research Journal of Medical Sciences VL - 18 IS - 10 SP - 629 EP - 632 PY - 2024 DA - 2001/08/19 SN - 1815-9346 DO - makrjms.2024.10.629.632 UR - https://makhillpublications.co/view-article.php?doi=makrjms.2024.10.629.632 KW - Non‐segmental vitiligo KW - oral corticosteroids KW - minipulse therapy KW - VASI KW - randomized controlled trial AB -

Rapidly progressive non‐segmental vitiligo (NSV) is a challenging autoimmune condition characterized by widespread depigmentation. Oral corticosteroids and minipulse therapy are commonly used immunosuppressive treatments, but their comparative efficacy and safety remain unclear. This randomized controlled study included 50 patients with rapidly progressive NSV. Patients were randomly assigned into two groups: Group A (n=25) received daily oral corticosteroids and Group B (n=25) underwent oral corticosteroid minipulse therapy. The primary outcome was the reduction in the Vitiligo Area Scoring Index (VASI) at 12 weeks. Secondary outcomes included disease stabilization, safety profile, and patient satisfaction. Statistical analysis was performed using Student’s t‐test and chi‐square tests. Both groups showed significant improvement in VASI scores at 12 weeks. Group A demonstrated greater reduction (mean VASI: 4.2±1.6) compared to Group B (mean VASI: 6.3±1.9, p=0.001). Disease stabilization was achieved in 88% of Group A and 76% of Group B (p=0.23). Adverse events such as weight gain (56% vs. 24%, p=0.02) and mood changes (40% vs. 12%, p=0.01) were more frequent in Group A. Patient satisfaction was higher in Group A (72%) than Group B (64%, p=0.48), though not statistically significant. Daily oral corticosteroids were more effective in reducing VASI scores and stabilizing disease activity but were associated with a higher incidence of adverse events. Minipulse therapy offers a safer alternative with moderate efficacy, making it suitable for long‐term management.

ER -